Agilent Technologies has introduced its InfinityLab Pro iQ Series mass detectors in India, setting a new benchmark in liquid chromatography-mass spectrometry (LC-MS) for pharmaceutical and biopharmaceutical applications. Designed to meet the evolving needs of scientists and manufacturers, the Pro iQ and Pro iQ Plus systems bring triple quadrupole-level sensitivity to a single quadrupole platform.

These next-generation detectors are engineered for advanced impurity profiling, trace contaminant detection, biomolecule characterisation, and mass-based purification. With robust performance across both small molecules and complex biologics—including oligonucleotides, peptides, and intact proteins—the Pro iQ Series enables high-resolution analysis while maintaining ease of use.

Smart automation and intuitive workflows are at the core of the system’s design, helping streamline operations in quality control, research, and manufacturing environments. The launch in India marks a significant milestone for Agilent in supporting the region’s growing pharmaceutical and contract research sectors.

At the unveiling event, key stakeholders from contract research organisations (CROs), contract development and manufacturing organisations (CDMOs), and pharmaceutical companies engaged in live demonstrations and hands-on sessions. The event also featured roundtable discussions led by Ian Edwards, Agilent’s Global Strategic Product Marketing Manager for LC/MS.

With India’s increasing focus on complex generics and biologics, the launch of the InfinityLab Pro iQ Series is expected to play a critical role in enhancing analytical capabilities for regulatory compliance, quality assurance, and innovative drug development.